Literature DB >> 26202894

Factors associated with atypical femoral fracture.

Dam Kim1,2, Yoon-Kyoung Sung1,2, Soo-Kyung Cho1,2, Minkyung Han2, Yee-Suk Kim3.   

Abstract

We aimed to investigate the proportion of atypical femoral fractures (AFF) among Korean femoral fracture patients and examined the factors associated with the development of AFF. Between 2003 and 2013, 607 female patients with low-energy femoral fractures who were hospitalized at a single university hospital were retrospectively enrolled in this study. Patients were classified into two groups according to the fracture site: Patients with subtrochanteric or diaphyseal femoral fractures were included in the AFF group, while patients with intertrochanteric or neck fractures were included in the typical femoral fracture (TFF) group. After comparing clinical and radiographic characteristics between groups, we used multivariable logistic regression analysis to explore risk factors for AFF. Thirty patients (4.9 %) with AFF and 577 patients (95.1 %) with TFF were identified. The AFF group was younger than the TFF group (p < 0.01), and more patients with AFF were treated with bisphosphonate (BP) (p < 0.01) or proton-pump inhibitor (p = 0.02). When comparing the radiographic parameters, the AFF group tended to have a higher cortical thickness index (p = 0.02) and lateral-to-medial cortex ratio (p < 0.01). After adjusting for clinical variables, BP use (OR 8.09, CI 3.09-21.19) and younger age (OR 1.06, CI 1.01-1.11) were associated with AFF. The proportion of AFF was 4.9 % among patients with femoral fractures. Younger age and use of BP before fracture increased the risk of development of AFF in Korean patients.

Entities:  

Keywords:  Atypical femoral fracture; Bisphosphonates; Proportion; Risk factor

Mesh:

Substances:

Year:  2015        PMID: 26202894     DOI: 10.1007/s00296-015-3323-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  31 in total

1.  Structural and cellular assessment of bone quality of proximal femur.

Authors:  L D Dorr; M C Faugere; A M Mackel; T A Gruen; B Bognar; H H Malluche
Journal:  Bone       Date:  1993 May-Jun       Impact factor: 4.398

2.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

3.  Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.

Authors:  Sylvie Perreault; Alice Dragomir; Alain Desgagné; Lucie Blais; Michel Rossignol; Julie Blouin; Yola Moride; Louis-Georges Ste-Marie; Julio Cesar Fernandès
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-10       Impact factor: 2.890

Review 4.  Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.

Authors:  John P Bilezikian
Journal:  Am J Med       Date:  2009-02       Impact factor: 4.965

Review 5.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

6.  Atypical fractures do not have a thicker cortex.

Authors:  V A Koeppen; J Schilcher; P Aspenberg
Journal:  Osteoporos Int       Date:  2012-10-18       Impact factor: 4.507

7.  Are race and sex associated with the occurrence of atypical femoral fractures?

Authors:  Alejandro Marcano; David Taormina; Kenneth A Egol; Valerie Peck; Nirmal C Tejwani
Journal:  Clin Orthop Relat Res       Date:  2013-10-29       Impact factor: 4.176

8.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Authors:  B A Lenart; A S Neviaser; S Lyman; C C Chang; F Edobor-Osula; B Steele; M C H van der Meulen; D G Lorich; J M Lane
Journal:  Osteoporos Int       Date:  2008-12-09       Impact factor: 4.507

Review 9.  Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.

Authors:  Serge C L M Cremers; Goonaseelan Pillai; Socrates E Papapoulos
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

10.  Atypical femoral fractures bilaterally in a patient receiving denosumab.

Authors:  Efstathios Drampalos; George Skarpas; Nikos Barbounakis; Ioannis Michos
Journal:  Acta Orthop       Date:  2013-10-31       Impact factor: 3.717

View more
  8 in total

1.  Atypical subtrochanteric fractures in Korean hip fracture study.

Authors:  Y-K Lee; T-Y Kim; Y-C Ha; S-H Song; J W Kim; H C Shon; J S Chang; K-H Koo
Journal:  Osteoporos Int       Date:  2017-06-14       Impact factor: 4.507

2.  Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure.

Authors:  Laura E Targownik; Andrew L Goertzen; Yunhua Luo; William D Leslie
Journal:  Am J Gastroenterol       Date:  2016-11-15       Impact factor: 10.864

3.  Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.

Authors:  J H Koh; J P Myong; J Yoo; Y-W Lim; J Lee; S-K Kwok; S-H Park; J H Ju
Journal:  Osteoporos Int       Date:  2017-07-27       Impact factor: 4.507

4.  Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia-not atypical at all.

Authors:  F Genest; L Seefried
Journal:  Osteoporos Int       Date:  2018-05-17       Impact factor: 4.507

5.  Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center.

Authors:  Noa Bareli; Roni Gat; Victoria Makarov; Ethel Siris; Merav Fraenkel; Uri Yoel
Journal:  Arch Osteoporos       Date:  2021-06-05       Impact factor: 2.617

6.  AN 'ATYPICAL' ATYPICAL FEMORAL FRACTURE.

Authors:  Richard Arneill; Matthew Arneill; Neville W Thompson; David Armstrong
Journal:  Ulster Med J       Date:  2019-10-11

7.  Atypical femoral fracture in a metastatic bone disease patient six months after discontinuation of denosumab received sequentially to previous bisphosphonate therapy - A case report.

Authors:  George F Georgiadis; Alexia P Balanika; Alexandros Ε Vasilakis; Dimitrios G Begkas; Christos S Baltas; Alexandros P Pastroudis
Journal:  J Musculoskelet Neuronal Interact       Date:  2021-09-01       Impact factor: 2.041

8.  The enigma of atypical femoral fractures: A summary of current knowledge.

Authors:  Morten Schultz Larsen; Hagen Schmal
Journal:  EFORT Open Rev       Date:  2018-09-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.